Logotype for Zeotech Limited

Zeotech (ZEO) Q2 2025 TU earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Zeotech Limited

Q2 2025 TU earnings summary

3 Dec, 2025

Executive summary

  • Signed a major MoU with Holcim Australia to collaborate on AusPozz™/OzPOS production and concrete trials, advancing industry partnerships and product validation.

  • Produced over 2 tons of OzPOS/AusPozz™ in pilot plant production, delivering 400kg to Holcim, 300kg to other customers, and additional samples to Europe and the USA.

  • Secured a Japanese patent for zeolite technology, expanding IP protection and commercial opportunities in Japan.

  • Early-stage methane control trials showed 70-85% reduction efficiency using zeoteCH4® products, with university trials showing up to 80% methane absorption.

  • Progressed PFS with expert consultants, initiated final geotech drilling, and appointed a Chief Commercial Officer to lead the feasibility study.

Financial highlights

  • Raised over AUD 1.8 million ($1.82 million) through a well-supported placement, ensuring funding for ongoing operations and PFS.

  • Received an AUD 900,000 ($905,884) R&D incentive and an AUD 145,000 Queensland Government Metz grant.

  • Cash position at 31 December 2024 was $2.503 million.

Outlook and guidance

  • PFS completion is on track for the second quarter of the year, with expectations for a high-quality, straightforward study.

  • Ongoing production and pilot concrete trials with Holcim and other partners to continue in 2025, with expansion of trials in Australia, Europe, and the USA.

  • Additional monitoring and data collection for methane control technology, with plans to move to on-site landfill trials.

  • Actively pursuing off-take agreements for DSO and OzPOS to secure early cash flow and support plant financing.

  • Anticipating release of internal OzPOS testing data by the end of the month or early next month.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more